Cardiovascular disease and the microbiome

Cardiovascular disease is responsible for nearly 18 million deaths worldwide.¹ Interestingly, research has shown that it may be possible to treat common conditions such as atherosclerosis, and metabolic syndrome earlier than first thought, based on the chemistry and balance of our gastrointestinal flora.

In a recent 2022 study,¹ the role of metabolites produced by the microbiota and the influence and therapeutic targeting of the gut microbiome in conditions such as atherosclerosis, chronic kidney disease (CKD), hypertension and cancer were explored, with intestinal dysbiosis being a key risk factor in each of these conditions.